Results from a recent phase 2 clinical trial of ilixadencel plus sunitinib for the treatment of newly-diagnosed metastatic renal cell carcinoma (RCC) were presented at the 2020 American Society of Clinical Oncology (ASCO)/Society for Immunotherapy of cancer (SITC) Clinical Immuno-Oncology Symposium, in Orlando, Florida, in February.
Ilixadencel is an immune primer designed to increase the body’s defence against cancer cells. It uses immune cells called dendritic cells, which play a key role in the activation of T-cells, immune cells that destroy cancer cells. The study discovered that addition of ilixadencel to standard surgical and medical treatment for newly-diagnosed metastatic RCC increases patient responses, duration of response, and appears to help people live longer. However, more time and study is needed to confirm the survival data, researchers say.